| Previous Close | 33.54 |
| Open | 33.47 |
| Bid | 33.50 x 200 |
| Ask | 33.57 x 400 |
| Day's Range | 33.39 - 33.58 |
| 52 Week Range | 29.83 - 37.39 |
| Volume | 12,024,304 |
| Avg. Volume | 20,610,738 |
| Market Cap | 199.8B |
| Beta | 1.07 |
| PE Ratio (TTM) | 28.18 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.81%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
Zacks•9 hours agoHCA Healthcare (HCA) Q2 Earnings: Will it Beat Estimates?
HCA Healthcare's (HCA) second-quarter earnings are likely to witness equivalent, admission growth and accretion from a number of acquisitions. Commercial business will likely be a dampener.
- Market Realist•9 hours ago
A Look at Johnson & Johnson’s Segment-Wise Performance
Johnson & Johnson (JNJ) reported a revenue increase of ~2.9% between 2Q16 and 2Q17. The company’s business is broken down into three business segments: Pharmaceuticals, Consumer Products, and Medical Devices. ...
- Zacks•11 hours ago
Can Merck (MRK) Pull Off a Surprise this Earnings Season?
Merck & Co., Inc.'s (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q2. However, headwinds remain in the form genericization of key drugs and increasing competition.
